High-Level Overview
Nina Capital is a specialized venture capital firm founded in 2019 and headquartered in Barcelona, focusing exclusively on early-stage health technology companies with global ambitions. Its mission is to invest in need-driven founders who develop innovations in diagnostics, medical devices, clinician training, healthcare infrastructure, and data-driven clinical pathways. The firm typically invests between €200,000 and €1.5 million initially, reserving capital for follow-on rounds. Nina Capital manages over €100 million in assets across three funds and has a portfolio of more than 50 companies spanning Europe, North America, Israel, Canada, and Australia. The firm supports startups by combining strategic insight, operational hands-on support, and a methodology inspired by Stanford Biodesign to help founders scale internationally[1][3].
Origin Story
Nina Capital was founded in 2019 by Marta G. Zanchi, who was inspired by the Biodesign process and motivated to support European need-driven founders at the intersection of healthcare and technology. Marta’s background includes extensive experience in digital health startups, international healthcare projects, and investment roles in Israel and Europe. The firm was launched in Barcelona, a city Marta identified as a promising hub for health tech innovation. The founding team includes key partners such as Marc Subirats (General Partner) and Jordi Pedrol (Head of Finance), who bring complementary expertise in finance, health, and technology investments. The firm evolved from Marta’s vision to create a venture capital firm that not only provides capital but also operational and strategic support to health tech startups aiming for international growth[1][4][6].
Core Differentiators
- Specialized Focus: Exclusive investment in health technology at the early stage, avoiding drugs and vaccines, with a focus on diagnostics, devices, clinical pathways, and healthcare infrastructure.
- Investment Model: Initial investments ranging from €200K to €1.5M with capital reserved for follow-on rounds, enabling sustained support.
- Strategic Support: Application of the Stanford Biodesign-inspired methodology to help founders identify real needs and scale solutions effectively.
- Global Network: Portfolio companies span multiple continents, supported by a diverse team with expertise in health, technology, digital, and investment industries.
- Experienced Team: Led by founder Marta G. Zanchi and supported by partners and advisors with deep industry and investment experience.
- Hands-On Approach: Operational involvement beyond capital, including strategic guidance and leveraging a broad international network to accelerate growth[1][3][6].
Role in the Broader Tech Landscape
Nina Capital rides the growing global trend of digital transformation in healthcare, where technology-driven solutions are increasingly critical to improving patient outcomes, clinician efficiency, and healthcare infrastructure. The timing is favorable due to rising demand for innovative diagnostics, data-driven clinical pathways, and scalable medical devices amid healthcare system pressures worldwide. By focusing on need-driven founders and applying a rigorous Biodesign approach, Nina Capital influences the ecosystem by fostering startups that address real clinical challenges, thereby accelerating the adoption of impactful health tech innovations. Its international reach and operational support help bridge European health tech innovation with global markets, contributing to a more connected and effective health technology ecosystem[1][4].
Quick Take & Future Outlook
Looking ahead, Nina Capital is poised to continue expanding its portfolio and influence in the health tech sector, leveraging its recently closed €50 million Fund III to back more startups with international ambitions. Trends such as AI in diagnostics, personalized medicine, and digital health infrastructure will likely shape its investment focus. The firm’s commitment to operational support and strategic scaling positions it well to help startups navigate complex healthcare markets and regulatory environments. As healthcare systems worldwide increasingly embrace technology, Nina Capital’s role as a specialized, hands-on investor will likely grow, further cementing its influence in shaping the future of health technology innovation[1][3].
